Sonoma Pharmaceuticals Inc. (SNOA)
$1.29
$0.00 (0.00%)As on 02-Sep-2026 14:35EDT
Market cap
$6 Mln
Revenue (TTM)
$22 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
11.5
-
Debt to Equity
0.3
-
Book Value
$--
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
4,788,425
10 Years Aggregate
CFO
$-71.02 Mln
EBITDA
$-81.84 Mln
Net Profit
$-49.28 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sonoma Pharmaceuticals (SNOA)
| -64.6 | 17.3 | 8.9 | -71.0 | -58.8 | -59.9 | -47.0 |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sonoma Pharmaceuticals (SNOA)
| 35.3 | -25.1 | -83.9 | -75.4 | -37.2 | 66.5 | -32.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sonoma Pharmaceuticals (SNOA)
|
1.3 | 6.3 | 21.9 | -2.3 | -6.2 | -45.2 | -- | 1.0 |
| 18.2 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 209.0 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 76.2 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 110.4 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.2 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.8 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 287.0 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 67.9 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 130.8 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Sonoma Pharmaceuticals (SNOA)
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin... America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado. Read more
-
CEO, President & Director
Ms. Amy M. Trombly
-
CEO, President & Director
Ms. Amy M. Trombly
-
Headquarters
Boulder, CO
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Sonoma Pharmaceuticals (SNOA)
What is the current share price of Sonoma Pharmaceuticals Inc (SNOA) Today?
The share price of Sonoma Pharmaceuticals Inc (SNOA) is $1.29 (NASDAQ) as of 02-Sep-2026 14:35 EDT. Sonoma Pharmaceuticals Inc (SNOA) has given a return of -58.77% in the last 3 years.
What is the current PB & PE ratio of Sonoma Pharmaceuticals Inc (SNOA)?
Since, TTM earnings of Sonoma Pharmaceuticals Inc (SNOA) is negative, P/E ratio is not available.
The P/B ratio of Sonoma Pharmaceuticals Inc (SNOA) is 0.97 times as on 28-Aug-2026, a 87 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
-1.18 |
1.21 |
2025 |
-0.79 |
0.62 |
2024 |
-0.03 |
0.02 |
2023 |
-0.09 |
0.06 |
2022 |
-2.44 |
1.43 |
What is the 52 Week High and Low of Sonoma Pharmaceuticals Inc (SNOA)?
The 52-week high and low of Sonoma Pharmaceuticals Inc (SNOA) are Rs 4.77 and Rs 0.85 as of 03-Sep-2026.
What is the market cap of Sonoma Pharmaceuticals Inc (SNOA)?
Sonoma Pharmaceuticals Inc (SNOA) has a market capitalisation of $ 6 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Sonoma Pharmaceuticals Inc (SNOA)?
Before investing in Sonoma Pharmaceuticals Inc (SNOA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.